SageView Advisory Group LLC Acquires New Position in Smith & Nephew plc (NYSE:SNN)

SageView Advisory Group LLC bought a new position in Smith & Nephew plc (NYSE:SNN) during the first quarter, Holdings Channel.com reports. The institutional investor bought 9,823 shares of the medical equipment provider’s stock, valued at approximately $249,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Nomura Holdings Inc. acquired a new position in Smith & Nephew during the fourth quarter worth $887,000. Clark Estates Inc. NY boosted its holdings in Smith & Nephew by 18.2% in the 4th quarter. Clark Estates Inc. NY now owns 650,000 shares of the medical equipment provider’s stock valued at $17,732,000 after purchasing an additional 100,000 shares during the last quarter. Scharf Investments LLC grew its stake in shares of Smith & Nephew by 20.5% in the 4th quarter. Scharf Investments LLC now owns 2,980,334 shares of the medical equipment provider’s stock valued at $81,304,000 after buying an additional 506,474 shares during the period. Wells Fargo & Company MN increased its holdings in shares of Smith & Nephew by 20.9% during the 4th quarter. Wells Fargo & Company MN now owns 1,003,050 shares of the medical equipment provider’s stock worth $27,363,000 after buying an additional 173,448 shares during the last quarter. Finally, Seed Wealth Management Inc. acquired a new position in Smith & Nephew in the fourth quarter valued at approximately $213,000. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Smith & Nephew Stock Down 0.3 %

NYSE SNN traded down $0.08 on Friday, reaching $28.11. The stock had a trading volume of 236,431 shares, compared to its average volume of 959,279. Smith & Nephew plc has a 12-month low of $21.52 and a 12-month high of $31.31. The stock has a fifty day moving average price of $25.85 and a two-hundred day moving average price of $26.26. The company has a quick ratio of 0.72, a current ratio of 1.77 and a debt-to-equity ratio of 0.44.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on SNN. UBS Group raised Smith & Nephew from a “neutral” rating to a “buy” rating in a research note on Wednesday, June 5th. StockNews.com downgraded Smith & Nephew from a “strong-buy” rating to a “buy” rating in a research report on Monday, May 13th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy”.

Smith & Nephew Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.